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The jerantinine family of Aspidosperma indole alkaloids from Tabernaemontana corymbosa are potent 
microtubule-targeting agents with broad spectrum anticancer activity. The natural supply of these 
precious metabolites has been significantly disrupted due to the inclusion of T. corymbosa on the 
endangered list of threatened species by the International Union for Conservation of Nature. This 
report describes the asymmetric syntheses of (−)-jerantinines A and E from sustainably sourced 
(−)-tabersonine, using a straight-forward and robust biomimetic approach. Biological investigations 
of synthetic (−)-jerantinine A, along with molecular modelling and X-ray crystallography studies of the 
tubulin—(−)-jerantinine B acetate complex, advocate an anticancer mode of action of the jerantinines 
operating via microtubule disruption resulting from binding at the colchicine site. This work lays the 
foundation for accessing useful quantities of enantiomerically pure jerantinine alkaloids for future 
development.
Natural products have made an enormous contribution in the treatment of cancer, with over half of the current 
anticancer drugs in clinical use being natural products or natural product derivatives1–3. Sometimes, however, 
there are disadvantages when using natural products as lead structures in drug discovery. Typically isolated from 
source in only minute quantities, the challenge of accessing useful quantities of these precious metabolites can 
present significant bottlenecks for development. This is particularly conspicuous when the natural supply has 
been exhausted and, in such instances, synthesis remains the only viable option. However, secondary metabolites 
are often incredibly challenging targets with unprecedented molecular connectivity and structural complexity4, 
and even when successful, total synthesis does not always result in adequate quantities of material for develop-
mental studies5,6.
The tubulin binding7,8 Vinca indole alkaloids, including vincristine and vinblastine are classic examples of 
structurally complex natural products that are among the foremost drugs used in cancer chemotherapy1–3,9. 
However, owing to their structural complexity, the de novo synthesis of these important drugs remains a signif-
icant challenge10,11, and clinical supplies of vincristine and vinblastine primarily rely upon natural sources10–15. 
Another major limitation to the continued use of the Vinca alkaloids is the emergence of drug resistance, derived 
primarily from the overexpression of phosphoglycoprotein (Pgp) efflux pump, that is responsible for transporting 
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many of the major drugs out of the cell16,17. Accordingly, the discovery and synthesis of bioactive alkaloids that 
overcome these resistance mechanisms is of high priority for anticancer drug development.
In 2008, several new Aspidosperma indole alkaloids, (−)-jerantinines A–G, were isolated by Kam and 
co-workers, from a leaf extract of the Malayan Tabernaemontana corymbosa Roxb. ex Wall18. The jerantinines 
displayed pronounced in vitro cytotoxicity toward drug-sensitive as well as vincristine-resistant (VJ300) KB 
cells (IC50 < 1 μg/mL)18, which is uncommon among simple Aspidosperma alkaloids. Studies have shown that 
both (−)-jerantinines A (1) and E (3) are microtubule-destabilising agents (MDAs)19,20, whereas 1 also induces 
tumour-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)21.
The antiproliferative and pro-apoptotic activities of the jerantinines via mechanisms involving perturbation 
of validated antitumor targets warrant further investigation as potential chemotherapeutic agents. However, 
the inclusion of T. corymbosa on the endangered list of threatened species by the International Union for 
Conservation of Nature (IUCN)22, limits the source of these natural compounds, and a practical synthetic route 
is urgently required.
To date, there have been only three reported synthetic studies towards the jerantinine alkaloids. Waser et 
al. reported the first synthesis of jerantinine E (3), which involved a key homo-Nazarov cyclisation of an ami-
nocyclopropane to access four of the five rings, leading to racemic (±)-(3) in 17-steps and 16% overall yield20. 
In 2017, Magauer and co-workers described a convergent synthesis to the ABC ring system of jerantinine E (3) 
that employed a β-C–H enone bromination followed by a palladium-catalysed amination and oxidative indole 
formation to yield a tricyclic core23.
Very recently, Jiang and co-workers completed the first total syntheses of (−)-jerantinines A (1), C (2) and E 
(3) in 12–13 steps24. The key steps of this route included a stereoselective intramolecular inverse-electron demand 
[4 + 2] cycloaddition, an α,β-unsaturated ketone indolisation and a Pd/C-catalysed cascade reaction.
Continuing our work on the biomimetic synthesis of natural products25–27, we report here the asymmetric 
and sustainable semi-syntheses of both (−)-jerantinine A (1) and (−)-jerantinine E (3), and provide supporting 
biological and structural data to further advocate a mechanism of action of the jerantinines via microtubule 
disruption.
The indole alkaloid (−)-tabersonine (4) was proposed as a plausible precursor to the jerantinines — diverging 
from the vindoline biosynthetic pathway28,29, a selective C-1530 A-ring oxidation of 16-methoxytabersonine (5) 
would give 1 directly31,32. Alternatively, the C16 ortho-hydroxylation and subsequent methylation of the metabo-
lite melodinine P (6) (from Melodinus suaveolens) would directly give 1 (Figs 1 and 2)33.
Thus, inspired by Nature’s efficiency in creating vast numbers of complex molecules from a single precursor, 
and the opportunity to exploit a readily available and sustainable natural feedstock, we elected to explore taberso-
nine (4) as a platform for synthetic elaboration into (−)-jerantinine A (1)34–36.
Studies commenced with the multi-gram scale extraction of 4 from the ground seeds of Voacanga Africana37,38, 
giving consistent yields of up to 1.4% by mass recovery. The reaction of 4 with N-iodosuccinimide in TFA at 
room temperature gave exclusively the 15-iodotabersonine (11) in 94% yield39. We anticipated that a Miyaura 
borylation followed by oxidation would conveniently install the required C-15 hydroxyl40–42, but upon experi-
mentation we found that protection of the indoline nitrogen was first required to prevent unwanted side reac-
tions. Gratifyingly, the N-Boc-iodotabersonine 12 reacted smoothly to give the boronate ester 13, which upon 
exposure to NMO yielded hydroxytabersonine 14 in 93% yield over 2 steps41. The next challenge was to install 
the critical C-16 hydroxyl, and we elected here to investigate a classical ortho-formylation followed by Dakin oxi-
dation sequence; given the sterically more encumbered C-14 ring position, we were confident that this could be 
achieved with good regiochemical control. This proved to be robust and convenient; thus, upon treatment of the 
Boc-protected 14 with paraformaldehyde in the presence of MgCl2 and Et3N, the C-16-aldehyde 15 was isolated 
in 98% yield43. Exposing 15 to a solution of hydrogen peroxide with a trace amount of SeO244 in tert-butanol 
gave a complex mixture, and therefore an operationally convenient one-pot procedure was developed; aldehyde 
Figure 1. A selection of Vinca and Aspidosperma alkaloids.
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15 was fully oxidised to the quinone, back-reduced with sodium dithionite and the catechol trapped by meth-
ylation to give the dimethoxy derivative 16 in 53% yield. Finally, sequential N-Boc deprotection and selective 
demethylation under Waser’s conditions20, furnished (−)-jerantinine A (1) in 72% yield, and 29% overall yield 
from (−)-tabersonine (4). Synthetic jerantinine A (1) was shown to be identical to natural jerantinine A through 
comparison of their 1H and 13C NMR spectroscopic data (Table S1). The conversion of 1 into (−)-jerantinine E 
(3) was accomplished upon selective reduction of the Δ6,7 double bond through H2 over PtO2 in 77% (23% overall 
yield, Scheme 1).
With significant amounts of synthetic 1 and synthetic intermediates en route to 1, we next explored the cyto-
toxicity of these molecules (See SI, Table S-2). The human-derived MCF-7 breast and HCT116 colorectal carci-
noma cell lines were chosen, since they are representative of two of the most prevalent types of cancer. In vitro 
antitumour activity of synthetic 1 was indistinguishable from the natural compound; for example, in MTT tests 
GI50 values <1 μM against colorectal and mammary human-derived carcinoma cell lines were observed for both 
samples of 1 (Table 1) - dose-response profiles are shown in supplementary data (Fig. S-1). Furthermore, both 
the synthetic and natural 1 dramatically and significantly inhibited colony formation of HCT116 cells when 
treated at the GI50 concentration (Fig. 3A). Cell cycle analyses demonstrated that at 0.8 µM, both natural and 
synthetic 1 profoundly perturbed the cell cycle, causing stark arrest at G2/M phase (See SI, Fig. S-1). Collectively, 
these data advocate that mitotic microtubule assembly has been disrupted. Indeed, at 1 μM naturally sourced and 
synthetic (−)-1 both abolished tubulin polymerisation in vitro as profoundly as the 5 μM nocodazole control 
(Fig. 3B). MCF-7 cells were treated for 24 h with 0.8 µM 1, stained (DRAQ5 and monoclonal anti α-tubulin Ab) 
and the images viewed by confocal microscopy. As shown in Fig. 3C, many characteristic features of the action of 
a microtubule disrupting agent (MDA) were observed, including formation of multipolar spindles, misaligned 
chromosomes, multinucleation (aneuploidy) and nuclear fragmentation45,46.
Following these results, we tested the impact of jerantinine A (1) and colchicine on breast cancer cell growth 
in 3D culture (Fig. 4). After 96 h of exposure to either agent, the cell density of both cell lines (measured as area) 
was decreased compared to control (Fig. 4B and C). Jerantinine A (1) decreased cell density of the MDA-MB-231 
to a greater extent than colchicine following 96 h of exposure (Fig. 4B). The invasive nature of the MDA-MB-231 
triple negative breast cancer cell line was also decreased by treatment with jerantinine A (1) or colchicine.
Figure 2. (A) Speculative biosynthetic pathway of jerantinine A and related vinca alkaloids (1) (B) Sustainable 
biomimetic semi-synthesis of (−)-jerantinine A (1) and (−)-jerantinine E (3), beginning from the proposed 
biogenetic precursor, (−)-tabersonine (4).
mean GI50 ± SD (μM)
Natural 1 Synthetic 1 Colchicine
HCT116 0.76 ± 0.13 0.82 ± 0.07 0.03 ± 0.01
MCF-7 0.85 ± 0.09 0.81 ± 0.07
Table 1. GI50 values of natural product and synthetic jerantinine A (1) and colchicine against human-derived 
colorectal (HCT116) and mammary (MCF-7) carcinoma cell lines. Data calculated from n ≥ 3 trials; n = 8 per 
concentration point per trial.
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Soaking experiments with a selection of the jerantinine metabolites and derivatives into a crystal formed 
by a protein complex composed of two αβ-tubulin heterodimers, the stathmin-like protein RB3 and tubulin 
tyrosine ligase (T2R-TTL)47,48, yielded the tubulin-jerantinine B acetate (9) structure at 2.4 Å resolution (Fig. 5A; 
Figure 3. (A) Effect of natural and synthetic 1 on HCT-116 colony formation at GI50 (see Table 1). Mean 
survival fraction (%) of treated cells as a percentage of the control population for HCT-116. Cells were seeded 
(400 per well) and allowed 24 h to attach before being challenged with jerantinine A (24 h). The number of 
colonies forming after 8 d incubation was determined. Mean (±S.E.M.) values are given. Data were generated 
from ≥3 separate trials; n = 2 per trial; (B) In vitro tubulin polymerisation in the presence of vehicle control, 
paclitaxel (5 μM; positive control), nocodazole (5 μM; negative control) or 1 (1 µM); (C) Immunofluorescent and 
DRAQ5 staining of x) untreated MCF-7 cells and y-z) cells exposed to synthetic 1 (1 × GI50 = 0.81 μM; 24 h), 
showing the effect on microtubules (green) and the cellular DNA (purple). Synthetic (−)-jerantinine A (1) 
caused multinucleation (i), nuclear fragmentation (ii) and formation of multipolar spindles (iii).
Figure 4. (A) MDA-MB-231 and MCF-7 breast cancer cells grown in 3D culture with vehicle (DMSO), 
jerantinine A (1) (5.36 µM or 1.22 µM‚ respectively) or colchicine (10 µM or 14.5 µM‚ respectively). Images from 
96 h post agent exposure. Scale bar represents 200 µm. (B) Quantification of the area of the MDA-MB-231 3D 
colonies over a 96 h period post agent addition. Mean (±S.E.M.) values are given. (C) Quantification of the area 
of the MCF-7 3D colonies over a 96 h period post agent addition. Mean (±S.E.M.) values are given. Data were 
generated from ≥2 separate trials; n = 2 per trial; *p < 0.05, **p < 0.01, ****p < 0.0001.
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Table S-3). The overall structure of the two tubulin dimers in the T2R-TTL-9 complex superimposed well with the 
one obtained in the absence of a ligand49 (Fig. S-3A; rmsdoverall of 0.48 Å over 1814 Cα-atoms; rmsdchain B 0.24 Å 
over 351 Cα-atoms). This result suggests that binding of the ligand does not affect the gross conformation of 
tubulin. Thus, the complex structure reveals that 9 binds to the colchicine site of tubulin that is shaped by residues 
of strands βS8 and βS9, loop βT7, and helices βH7 and βH8 of β-tubulin, and loop αT5 of α-tubulin (Fig. 5B).
Superimposition of the tubulin-9 structure onto the tubulin-colchicine structure (rmsd of 0.204 Å over 
351 Cα-atoms, chain B)49 revealed a perfect overlap of the jerantinine A-ring of 9 with the C-ring of colchicine 
and two major conformational changes in the binding site of 9 (Fig. 5C). In the jerantinine structure, Thr179 on 
the αT5 loop is in the flipped-in conformation and forms a hydrophobic contact to Leu248 on the βT7 loop. In 
the colchicine structure Thr179 is in the flipped-out conformation to avoid clashes with the acetamide moiety. 
Moreover, jerantinine-binding induces a rearrangement of Leu248 on the βT7 loop to prevent clashes with the 
epoxide moiety on the D-ring of 9 (Fig. 4C), and of Ala250 and Leu255 to fill the space that is otherwise occupied 
by the A-ring of colchicine.
Tubulin dimers in microtubules assume a “straight” structure; in contrast, free tubulin is characterised by a 
“curved” conformation50,51. The jerantinine B acetate (9) prevents the curved-to-straight structural transition by 
sterically hindering the βT7 loop adopting its conformation characteristic of the straight tubulin state (Fig. S-3B), 
a mechanism that is similar to other colchicine-site ligands49,51–53.
Subsequent molecular docking studies revealed a distinct preference of jerantinines A (1) and E (3) for the 
colchicine pocket (Fig. 5D, Table S-4)54. Binding energies to either the vinblastine or taxol sites were approxi-
mately 10 and 15 kJ mol−1, respectively, lower than the colchicine site. Jerantinine B acetate (9) was calculated 
as the tightest binding ligand of the family, and was predicted to bind ~5 kJ mol−1 more tightly than colchicine. 
The structure of jerantinine B acetate closely matches the experimentally determined structure – rmsd of 0.68 Å. 
The predicted binding orientation of all the jerantinine derivatives, in the colchicine binding site, mirror that of 
jerantinine B acetate (9).
In conclusion, we have described the asymmetric synthesis of the Aspidosperma alkaloid (−)-jerantinine A 
(1) in 9 steps and 29% overall yield, using a sustainable semi-synthetic approach. The selective reduction of (−)-1 
enabled the asymmetric synthesis of the corresponding (−)-jerantinine E (3). Our biomimetic approach began 
Figure 5. Crystal structure of the tubulin-jerantinine B acetate (9) complex. (A) Overall view of the T2R-
TTL-jerantinine B acetate complex structure. The α- and β-tubulin chains are in dark and light grey ribbon 
representation, respectively. The tubulin-bound 9 and GTP molecules are represented as green and orange 
spheres, respectively; (B) Close-up view of the interactions observed between 9 (green) and tubulin (grey). 
Interacting residues of tubulin are shown in stick representation and are labelled. Oxygen and nitrogen atoms 
are coloured red and blue, respectively; carbon atoms are in green 9 or grey (tubulin). Secondary structural 
elements of tubulin are labelled in blue. For simplicity, only α-tubulin residues are indicated with an α; (C) 
Superimposition of the tubulin-9 (green/grey) and the tubulin-colchicine (pink; PDB ID 4O2B; rmsd of 0.204 Å 
over 351 Cα-atoms) complex structures. The structures were superimposed onto their β1-tubulin chains; (D) 
Molecular docking of (−)-jerantinine A (1) in the colchicine binding pocket of tubulin; this pocket is formed by 
residues in the αT5-loop on α-tubulin, and βH7, βH8, βS8, βS9 and the βT7-loop on β-tubulin. For additional 
experimental details see the Supporting Information.
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from the natural building block and plausible biosynthetic precursor (−)-tabersonine (4), that is readily avail-
able in large quantities from a sustainable plant-based source (Voacanga Africana). The synthesis enabled us to 
investigate the biological profile of (−)-jerantinine A (1), showing that activity of synthetic 1 is indistinguishable 
from that of the natural material against human derived breast (MCF-7) and colon carcinoma (HCT116) cell 
lines. A 3D culture assay showed that jerantinine A (1) decreased the cell density of two breast cancer cell lines, 
in particular demonstrating greater effectiveness than colchicine against MDA-MB-231 cells. Investigations into 
the mode of action suggested that 1 acts via disruption of the microtubule network, as indicated by its potent 
inhibitory activity displayed in tubulin polymerisation in vitro. This particular mode of action was further cor-
roborated by solving of the crystal structure of the tubulin—jerantinine B acetate complex, revealing binding to 
the colchicine site and prevention of the “curved-to-straight” tubulin conformational transition that is necessary 
to enable microtubule formation.
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